Literature DB >> 23664467

American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients.

Carol L Shields1, Swathi Kaliki, Minoru Furuta, Enzo Fulco, Carolina Alarcon, Jerry A Shields.   

Abstract

PURPOSE: To evaluate the clinical features and prognosis of posterior uveal (ciliary body and choroid) melanoma based on the American Joint Committee on Cancer (AJCC) classification (7th edition) of primary tumor (T).
DESIGN: Retrospective, interventional case series. PARTICIPANTS: Seven thousand seven hundred thirty-one patients. INTERVENTION: Ocular management including plaque radiotherapy, enucleation, local resection, or laser therapy. MAIN OUTCOME MEASURES: Melanoma-related metastasis and death.
RESULTS: Of 7731 patients with posterior uveal melanoma, the AJCC classification based on T was category T1 in 3557 (46%), T2 in 2082 (27%), T3 in 1599 (21%), and T4 in 493 (6%). Based on tumor categories T1, T2, T3, and T4, respectively, features that showed significant increase with tumor category included patient age at presentation (57, 58, 58, and 61 years; P<0.001), tumor base (8, 12, 15, and 20 mm; P<0.001), tumor thickness (3.5, 5.2, 8.9, and 11.4 mm; P<0.001), mushroom configuration (8%, 20%, 38%, and 39%; P<0.001), associated subretinal fluid (64%, 80%, 82%, and 83%; P<0.001), intraocular hemorrhage (5%, 12%, 17%, and 18%; P<0.001), rupture of Bruch's membrane (9%, 24%, 40%, and 40%; P<0.001), and extraocular extension (1%, <1%, 4%, and 12%; P<0.001). After therapy, Kaplan-Meier estimates of metastasis at 5, 10, and 20 years were 8%, 15%, and 25% for category T1, 14%, 25%, and 40% for category T2, 31%, 49%, and 62% for category T3, and 51%, 63%, and 69% for category T4, respectively (P<0.001). Kaplan-Meier estimates of death at 5, 10, and 20 years were 4%, 8%, and 11% for category T1, 8%, 13%, and 24% for category T2, 19%, 27%, and 36% for category T3, and 30%, 43%, and 51% for category T4, respectively (P<0.001). Compared with category T1, the hazard ratio for metastasis and death for T2 was 1.8 and 1.9, respectively, that for T3 was 4.5 and 4.7, respectively, and that for T4 was 8.2 and 8.8, respectively.
CONCLUSIONS: Based on the AJCC classification, increasing tumor category was associated with older age, larger tumor, and greater incidence of subretinal fluid, hemorrhage, and extraocular extension. Compared with uveal melanoma classified as T1, the rate of metastasis and death was 2 times greater for T2, 4 times greater for T3, and 8 times greater for T4. The risk for metastasis and death increased 2-fold with each increasing melanoma category. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23664467     DOI: 10.1016/j.ophtha.2013.03.012

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  42 in total

1.  CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.

Authors:  Duncan E Berry; Amy C Schefler; Michael I Seider; Miguel Materin; Sandra Stinnett; Prithvi Mruthyunjaya
Journal:  Retina       Date:  2018-11-08       Impact factor: 4.256

2.  IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma.

Authors:  Eric Londin; Rogan Magee; Carol L Shields; Sara E Lally; Takami Sato; Isidore Rigoutsos
Journal:  Pigment Cell Melanoma Res       Date:  2019-08-16       Impact factor: 4.693

3.  Surgery vs. radiotherapy in patients with uveal melanoma : Analysis of the SEER database using propensity score matching and weighting.

Authors:  Bum-Sup Jang; Ji Hyun Chang; Sohee Oh; Yu Jin Lim; Il Han Kim
Journal:  Strahlenther Onkol       Date:  2017-09-06       Impact factor: 3.621

4.  Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment.

Authors:  A Klingenstein; C Fürweger; A K Mühlhofer; S F Leicht; U C Schaller; A Muacevic; B Wowra; C Hintschich; K H Eibl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-16       Impact factor: 3.117

Review 5.  Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma.

Authors:  Erin E Nichols; Ann Richmond; Anthony B Daniels
Journal:  Semin Ophthalmol       Date:  2016-04-29       Impact factor: 1.975

6.  Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy.

Authors:  C Ellis Wisely; Mersiha Hadziahmetovic; Rachel E Reem; Erinn M Hade; Subir Nag; Frederick H Davidorf; Douglas Martin; Colleen M Cebulla
Journal:  Brachytherapy       Date:  2016 Jan-Feb       Impact factor: 2.362

Review 7.  Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture.

Authors:  C L Shields; S Kaliki; M N Cohen; P W Shields; M Furuta; J A Shields
Journal:  Eye (Lond)       Date:  2015-08-07       Impact factor: 3.775

Review 8.  [Uveal and iridociliary melanomas in young patients : A retrospective analysis of 57 cases].

Authors:  L J Heyer; C Metz; D Flühs; C M Heyer; N Bornfeld
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

9.  Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals.

Authors:  Carol L Shields; Lauren A Dalvin; Michael Chang; Mehdi Mazloumi; Patricia Fortin; Mark McGarrey; Andrei Martin; Antonio Yaghy; Xiaolu Yang; Pornpattana Vichitvejpaisal; Arman Mashayekhi; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2020-02-01       Impact factor: 7.389

10.  A pilot study to compartmentalize small melanocytic choroidal tumors and choroidal vessels with speckle-noise free 1050 nm swept source optical coherence tomography (OCT choroidal "tumoropsy").

Authors:  Peter Maloca; Cyrill Gyger; Pascal Willy Hasler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-30       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.